20th Mar 2017 07:00
20 MARCH 2017
|
NOTIFICATION OF MAJOR INTEREST BY LEGAL & GENERAL
ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 4,446,545 million Ordinary Shares in the capital of the Company, representing 3.35% of ImmuPharma's total voting rights figure of 132,522,985 Ordinary Shares.
Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to be able to disclose Legal & General's increased holding in ImmuPharma as one of our existing major institutional investors which participated in our recent successful £4.1 million fundraising demonstrating its continued support for ImmuPharma."
Full disclosure of the TR1 is shown below:
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES |
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:
| ImmuPharma Plc | |||
2. Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | Yes | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.
| ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
| ||||
An event changing the breakdown of voting rights | ||||
Other (please specify):
| ||||
3. Full name of person(s) subject to thenotification obligation: | Legal & General Group Plc (L&G) | |||
4. Full name of shareholder(s) (if different from 3.): | Legal & General Assurance Society Limited (LGAS) | |||
5. Date of the transaction and date onwhich the threshold is crossed orreached:
| 16 March 2017 | |||
6. Date on which issuer notified: | 17 March 2017 | |||
7. Threshold(s) that is/are crossed orreached:
| L&G (Above 3%) | |||
8. Notified details:
| ||||||||||||||
A: Voting rights attached to shares | ||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||
NumberofShares | NumberofVotingRights |
Numberof shares | Number of votingrights | % of voting rights | ||||||||||
Direct | Indirect | Direct | Indirect | |||||||||||
ORD GBP 0.10 |
Below 3%
| 4,446,545 | 4,446,545 | - | 3.35% | - | ||||||||
B: Qualifying Financial Instruments | ||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||
Type of financialinstrument |
Expirationdate |
Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. |
% of votingrights | ||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||
Type of financialinstrument
|
Exercise price |
Expiration date |
Exercise/Conversion period |
Number of voting rights instrument refers to
|
% of voting rights
| |||||||||
| Nominal | Delta | ||||||||||||
| ||||||||||||||
Total (A+B+C) | ||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||
(L&G)
4,446,545
|
3.35% | |||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||||||||||||||||||||||||
| ||||||||||||||||||||||||
Proxy Voting: | ||
10. Name of the proxy holder: | N/A | |
11. Number of voting rights proxy holder will ceaseto hold: | N/A | |
12. Date on which proxy holder will cease to holdvoting rights: | N/A | |
13. Additional information: | Notification using the total voting rights figure of 132,522,985 | |
14. Contact name: | Victoria Davies (LGIM) | |
15. Contact telephone number: | 029 2035 4147 | |
-Ends-
For further information please contact:
|
Related Shares:
ImmupharmaLegal & General